AbbVie reports record 2025 results as Merit Financial Group raises stake
AbbVie reported full-year adjusted EPS of $10 and total net revenue of $61.2 billion for 2025. Merit Financial Group raised its fourth-quarter stake in the company to 93,295 shares worth $21.317 million.
AbbVie Inc. reported full-year adjusted EPS of $10 and said it closed 2025 with record performance, above its initial guidance midpoint by $0.54 excluding IPR&D expenses. In the fourth quarter, Merit Financial Group LLC raised its stake in AbbVie by 13.7% to 93,295 shares, worth $21.317 million at the end of the most recent quarter.
Overall sales increased 8.6% year over year despite a significant U.S. Humira decline, and total net revenue reached $61.2 billion, more than $2 billion above initial expectations. AbbVie said it anticipates a 9.5% increase in overall revenues in 2026, mainly due to Skyrizi and Rinvoq, which are expected to generate a combined revenue of over $31 billion, surpassing previous long-term expectations.
The company also said it completed almost $5 billion in business development deals, advanced about 90 clinical studies, and boosted adjusted R&D investment by almost $1 billion in order to expand its pipeline across immunology, oncology, neuroscience, and obesity.
In its latest quarterly report, AbbVie reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. Revenue for the quarter was $16.62 billion, compared with analysts' expectations of $16.39 billion, and quarterly revenue was up 10.0% compared to the same quarter last year.
Other institutional investors also recently made changes to their positions in ABBV, and institutional investors own 70.23% of the company's stock. AbbVie shares opened at $209.00 on Friday, with a market cap of $369.55 billion.